Cantor Fitzgerald upgraded shares of Cypherpunk Technologies (NASDAQ:CYPH – Free Report) to a strong-buy rating in a research note published on Wednesday morning,Zacks.com reports.
Other research analysts have also issued reports about the company. Wall Street Zen lowered Cypherpunk Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings lowered Cypherpunk Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 25th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Cypherpunk Technologies currently has an average rating of “Moderate Buy” and a consensus price target of $0.90.
View Our Latest Research Report on Cypherpunk Technologies
Cypherpunk Technologies Stock Up 5.2%
Cypherpunk Technologies (NASDAQ:CYPH – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.42).
Hedge Funds Weigh In On Cypherpunk Technologies
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC acquired a new stake in shares of Cypherpunk Technologies during the fourth quarter valued at about $37,000. LPL Financial LLC purchased a new position in Cypherpunk Technologies in the fourth quarter valued at about $38,000. Caitong International Asset Management Co. Ltd acquired a new stake in Cypherpunk Technologies during the 4th quarter valued at approximately $44,000. Sequoia Financial Advisors LLC acquired a new stake in Cypherpunk Technologies during the 4th quarter valued at approximately $56,000. Finally, HighTower Advisors LLC purchased a new stake in Cypherpunk Technologies during the 4th quarter worth approximately $59,000. 30.46% of the stock is owned by hedge funds and other institutional investors.
About Cypherpunk Technologies
Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.
DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.
Further Reading
- Five stocks we like better than Cypherpunk Technologies
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Receive News & Ratings for Cypherpunk Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cypherpunk Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
